Osimertinib (Tagrisso, AstraZeneca) with pemetrexed and platinum-based chemotherapy is indicated for 'the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations'.
The dosage schedule is available in the summary of product characteristics for osimertinib.
The list price of osimertinib is £5,770 per pack of 30 tablets in either 40‑mg or 80‑mg doses (excluding VAT; BNF online accessed January 2025).
The list price of pemetrexed (25 mg/ml) varies between £128 and £160 per 4‑ml vial, between £640 and £800 per 20‑ml vial, between £1,280 and £1,600 per 40‑ml vial, and is £1,360 per 34‑ml vial (excluding VAT; BNF online accessed January 2025).
The company has a commercial arrangement. This makes osimertinib available to the NHS with a discount. The size of the discount is commercial in confidence.